COSTA MESA, Calif., April 21, 2026 /PRNewswire/ -- CerraCap Ventures investment in Nephronomics reflects strategic conviction of backing platforms that transform fragmented healthcare systems into predictive, precision-driven ecosystems. Nephronomics is a next-generation AI-bio precision medicine company. The company is building one of the world's most comprehensive clinical and genomic data sets focused on cardio-kidney-metabolic (CKM) disease—a rapidly emerging framework that links cardiovascular, kidney, and metabolic disorders into a unified disease model. Nephronomics' moat is built on data— in this AI era, data matters more than models. It has exclusive access to the largest renal dataset globally, spanning 42,000+ patients across a significant portion of U.S. dialysis clinics. This scale is difficult to replicate, positioning the company as a leader in data-driven kidney disease innovation. Nephronomics is translating this proprietary dataset into actionable biological insight using advanced machine learning. Its platform leverages state-of-the-art capabilities—including protein modeling, variant-effect prediction, and generative design—to identify new disease subtypes, uncover causal mechanisms, and develop novel therapeutic targets. This approach enables a shift from correlation to causation in drug discovery—accelerating the development of precision therapies that directly address disease-driving molecular pathways. The opportunity is significant, with chronic kidney disease affecting 14% of the U.S. population and...

CerraCap Ventures invests in Nephronomics, aiming to revolutionize kidney disease research through advanced AI and data analytics.

Azenta collaborates with Frenova and Nephronomics to advance genomic research in nephrology, aiming for breakthrough discoveries in kidney diseases.

Fresenius Medical Care's Frenova collaborates with Nephronomics and GENEWIZ to enhance genomic analysis, aiming for breakthroughs in precision kidney disease care.

New alliance combines 35,000-patient database with AI-powered genomics to unlock kidney disease breakthroughs. Discover how this partnership aims to transform patient care.

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registry...

Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin...